Based on the Repare Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for Repare Therapeutics Inc is USD 4.50 over the next 12 months. Repare Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Repare Therapeutics Inc is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Repare Therapeutics Inc’s stock price was USD 1.37. Repare Therapeutics Inc’s stock price has changed by +24.55% over the past week, +22.32% over the past month and -57.98% over the last year.
No recent analyst target price found for Repare Therapeutics Inc
No recent average analyst rating found for Repare Therapeutics Inc
Company Overview Repare Therapeutics Inc
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. Read Less
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer th...Read More
Frequently Asked Questions About Repare Therapeutics Inc (RPTX) Stock
Based on ratings from 2 analysts Repare Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on RPTX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for RPTX is USD 4.50 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on RPTX's stock to indicate if its overvalued.
The last closing price of RPTX's stock was USD 1.37.
The most recent market capitalization for RPTX is USD 0.04B.
Based on targets from 2 analysts, the average taret price for RPTX is projected at USD 4.50 over the next 12 months.
This means that RPTX's stock price may go up by +228.47% over the next 12 months.
We can't find any ETFs which contains Repare Therapeutics Inc's stock.
As per our most recent records Repare Therapeutics Inc has 129 Employees.
Repare Therapeutics Inc's registered address is 7171 Frederick-Banting, Building 2, Montreal, QC, Canada, H4S 1Z9.
You can get more information about it from Repare Therapeutics Inc's website at https://www.reparerx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Repare Therapeutics Inc (RPTX) Stock
Based on ratings from 2 analysts Repare Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on RPTX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for RPTX is USD 4.50 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on RPTX's stock to indicate if its overvalued.
The last closing price of RPTX's stock was USD 1.37.
The most recent market capitalization for RPTX is USD 0.04B.
Based on targets from 2 analysts, the average taret price for RPTX is projected at USD 4.50 over the next 12 months.
This means that RPTX's stock price may go up by +228.47% over the next 12 months.
We can't find any ETFs which contains Repare Therapeutics Inc's stock.
As per our most recent records Repare Therapeutics Inc has 129 Employees.
Repare Therapeutics Inc's registered address is 7171 Frederick-Banting, Building 2, Montreal, QC, Canada, H4S 1Z9.
You can get more information about it from Repare Therapeutics Inc's website at https://www.reparerx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RPTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
